Zoledronic Acid — CPB 0524 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0524 governing zoledronic acid coverage, effective February 14, 2026. Here's what billing teams need to know before submitting your next claim.

Aetna's updated zoledronic acid coverage policy under CPB 0524 Aetna system draws a sharp line between two formulations — the 5 mg dose (Reclast or generic, billed under HCPCS J3489) and the 4 mg dose (formerly Zometa) — with distinct medical necessity criteria for each. If your practice administers either formulation and bills infusion administration codes like CPT 96365 or 96366, this policy directly affects your prior authorization workflow and your claim approval rate. The policy covers commercial medical plans only; for Medicare criteria, Aetna points to a separate Part B step therapy policy.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Zoledronic Acid — CPB 0524
Policy Code	CPB 0524
Change Type	Modified
Effective Date	February 14, 2026
Impact Level	High
Specialties Affected	Oncology, rheumatology, endocrinology, urology, primary care (osteoporosis management)
Key Action	Audit active zoledronic acid authorizations against the updated 24-month continuation criteria before submitting renewal requests

---

Aetna Zoledronic Acid Coverage Criteria and Medical Necessity Requirements 2026

The real issue here is specificity. Aetna's CPB 0524 Aetna system does not grant broad coverage for zoledronic acid — it requires you to match the right formulation to the right indication with documented clinical evidence.

Zoledronic Acid 5 mg (Reclast or Generic) — Initial Approval

For postmenopausal osteoporosis, Aetna requires at least one of three things: a history of fragility fractures (low-trauma fractures from forces like a standing fall), a pre-treatment T-score at or below -2.5, or osteopenia (T-score between -1 and -2.5) with a high pre-treatment FRAX probability score. Your chart documentation must show which criterion applies before you submit for prior authorization.

Male osteoporosis follows nearly the same structure. Aetna requires a history of osteoporotic vertebral or hip fracture, a T-score at or below -2.5, or osteopenia with a high FRAX probability.

Glucocorticoid-induced osteoporosis adds an "and" — both conditions must be met. The member must be taking prednisone at 2.5 mg/day or more (or an equivalent glucocorticoid) for at least three months. They also must meet one of the three bone density or fracture history criteria above. Miss either condition and the claim denies.

Paget's disease of bone and prostate cancer treatment-related bone loss (in members on androgen deprivation therapy with drugs like leuprolide or goserelin) round out the covered 5 mg indications. Both are covered without additional sub-criteria beyond the diagnosis.

Zoledronic Acid 4 mg (Formerly Zometa) — Initial Approval

The 4 mg formulation targets oncology patients. Aetna covers it for prevention or treatment of skeletal-related events in members with bone metastases from solid tumors — breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, and prostate cancer are all examples in the policy. This is where your oncology billing team needs to pair the diagnosis ICD-10 with the HCPCS J3489 code and the appropriate infusion administration code (CPT 96365–96368) carefully.

Continuation of Therapy — The 24-Month Rule

This is where the policy gets operationally complex. Continuation criteria differ based on how long the member has been on therapy.

For members with less than 24 months of therapy, Aetna requires no clinically significant adverse events. That's the bar. For members at 24 months or beyond, two things must both be true: the member has experienced clinical benefit (improvement or stabilization in T-score since the last bone mass measurement), and the member has not experienced adverse effects.

The T-score comparison requirement at the 24-month mark means your prior auth renewal requests need bone density scan results attached. Don't send the renewal without them — Aetna will kick it back.

Paget's disease is handled separately. Continuation approval requires the member to meet all initial selection criteria at the time of renewal, including new members on existing therapy.

---

Aetna Zoledronic Acid Exclusions and Non-Covered Indications

Aetna's coverage policy is explicit: all indications not named in CPB 0524 are considered experimental, investigational, or unproven for the 5 mg formulation. There is no ambiguity here. If a provider wants to use Reclast for an off-label condition not on the covered list, the claim will deny.

For the oncology-side 4 mg formulation, the policy also excludes use as adjuvant or neoadjuvant treatment for non-small cell lung cancer and certain other malignancies. The ICD-10 code ranges for malignant neoplasms carry a specific note — coverage does not extend to adjuvant/neoadjuvant settings for several tumor types. Review the applicable diagnosis codes carefully. Billing a metastatic bone disease claim with an ICD-10 that Aetna reads as a primary tumor code without bone mets documentation is a common claim denial trigger.

Hypercalcemia coverage under ICD-10 E83.52 is limited to hypercalcemia due to malignancy only. If the hypercalcemia has another etiology, the claim will not clear.

---

Coverage Indications at a Glance

---

Aetna Zoledronic Acid Billing Guidelines and Action Items 2026

Your billing team has specific things to do before the February 14, 2026 effective date has passed — and several to do right now.

Copy Action Items

If the 24-month continuation criteria or the oncology exclusion language is unclear as applied to your specific patient population, talk to your compliance officer before submitting renewals under the updated policy. The stakes on a wrongly authorized infusion are high — reimbursement clawbacks from Aetna are painful and slow.

---

CPT, HCPCS, and ICD-10 Codes for Zoledronic Acid Under CPB 0524

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J3489	HCPCS	Injection, zoledronic acid, 1 mg

CPT Codes — Infusion Administration and Related Services

CPT Codes — Laboratory (Alkaline Phosphatase Monitoring)

Code	Type	Description Copy
84075	CPT	Phosphatase, alkaline
84078	CPT	Phosphatase, alkaline; heat stable (total not included)
84080	CPT	Phosphatase, alkaline; isoenzymes

Other HCPCS Codes Related to CPB 0524 (Bisphosphonate Class)

Key ICD-10-CM Diagnosis Codes

Note: The full policy references 226 ICD-10-CM codes. The table above reflects the codes provided in the policy data. Pull the complete code list from CPB 0524 on Aetna's site before finalizing your claim edits.

---